CSPHF - Roche Blueprint CStone's Gavreto gets approval in Hong Kong for lung cancer subtype

• Blueprint Medicines ( NASDAQ: BPMC ), CStone Pharmaceuticals ( OTCPK:CSPHF ) and Roche's ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) Gavreto was approved in Hong Kong for certain patients with non-small cell lung cancer (NSCLC).
• CStone said the the new drug application (NDA) for Gavreto (pralsetinib) was approved to treat adult patients with rearranged during transfection (RET) fusion-positive metastatic NSCLC. It includes both pre-treated patients and those who have not received prior therapy for the disease.
• CStone has a license agreement with Blueprint for Gavreto in Greater China, which includes Mainland China, Hong Kong, Macau and Taiwan.
• The approval was based a global phase 1/2 study called ARROW.
• Separately, it was reported that Pfizer backed CStone ( OTCPK:CSPHF ) is exploring strategic options, including a sale of the company.

For further details see: